Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

Endometrial cancer is the most common gynecologic malignancy in the US. While the majority of cases are diagnosed early and can be treated with surgery alone, for advanced or recurrent disease, the survival rate drops to below 20%. Immunotherapy-based regimens, such as immune checkpoint inhibitors, have shown promising results in improving survival and quality of life. While immunotherapy has shown significant promise, not all patients benefit, so identifying patients who are most likely to respond remains a challenge. This session will highlight best practices for appropriate use of immunotherapies in advanced endometrial cancer, outlining the utility of biomarker testing and translation to treatment selection. By developing protocols that advance precision medicine, ensure evidence-based sequencing of these therapies, and tailor treatment in gynecologic cancers, managed care and oncology pharmacists can play a crucial role in improving outcomes for patients. Strategies that incorporate immunotherapies into treatment plans and reduce inequities in medication access will also be discussed.

Target audience: Managed care pharmacists, oncology pharmacists

Type of activity: Application
Release date: April 8, 2025
Expiration date: April 8, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the molecular pathways and genetic factors implicated in endometrial cancer to identify appropriate treatment strategies based on a patient's individual tumor profile.
• Interpret the most recent clinical data and evolving treatment guidelines for current and emerging immune-based therapies in the management of endometrial cancer to identify effective and appropriate treatment options for patients.
• Determine best practices for managed care in integrating the latest clinical evidence on immune-based therapies for endometrial cancer to ensure equitable access, appropriate utilization, and optimal patient outcomes.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-082-H01-P. The activity is available for CE credit through April 8, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Laura R. Bobolts, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose: Consultant: Pfizer (steering committee participation).

Erin Hickey Zacholski, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose: Consultant: Verastem.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms